HK1114903A1 - Auxiliary method for diagnosis and therapy of cancer with nucleolin - Google Patents

Auxiliary method for diagnosis and therapy of cancer with nucleolin

Info

Publication number
HK1114903A1
HK1114903A1 HK08110478.2A HK08110478A HK1114903A1 HK 1114903 A1 HK1114903 A1 HK 1114903A1 HK 08110478 A HK08110478 A HK 08110478A HK 1114903 A1 HK1114903 A1 HK 1114903A1
Authority
HK
Hong Kong
Prior art keywords
nucleolin
endostatin
kit
antibody
diagnosis
Prior art date
Application number
HK08110478.2A
Other languages
English (en)
Inventor
Yongzhang Luo
Hubing Shi
Zhuobing Zhang
Original Assignee
Univ Tsinghua
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tsinghua, Protgen Ltd filed Critical Univ Tsinghua
Publication of HK1114903A1 publication Critical patent/HK1114903A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
HK08110478.2A 2005-05-12 2008-09-22 Auxiliary method for diagnosis and therapy of cancer with nucleolin HK1114903A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2005100117073A CN1862258B (zh) 2005-05-12 2005-05-12 核仁素辅助的癌症诊断与治疗方法
PCT/CN2006/000942 WO2006119706A1 (fr) 2005-05-12 2006-05-11 Procede auxiliaire de diagnostic et traitement du cancer a la nucleoline

Publications (1)

Publication Number Publication Date
HK1114903A1 true HK1114903A1 (en) 2008-11-14

Family

ID=37389730

Family Applications (2)

Application Number Title Priority Date Filing Date
HK08110478.2A HK1114903A1 (en) 2005-05-12 2008-09-22 Auxiliary method for diagnosis and therapy of cancer with nucleolin
HK12102802.0A HK1162667A1 (en) 2005-05-12 2012-03-20 Nucleolin as marker for determining the likelihood of success of endostatin cancer therapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK12102802.0A HK1162667A1 (en) 2005-05-12 2012-03-20 Nucleolin as marker for determining the likelihood of success of endostatin cancer therapy

Country Status (11)

Country Link
US (3) US20060258605A1 (da)
EP (2) EP2375251B1 (da)
JP (3) JP4742142B2 (da)
CN (2) CN1862258B (da)
AT (1) ATE516499T1 (da)
AU (2) AU2006246197B2 (da)
CA (1) CA2607832A1 (da)
DK (1) DK1912066T3 (da)
ES (2) ES2369383T3 (da)
HK (2) HK1114903A1 (da)
WO (1) WO2006119706A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CN1862258B (zh) 2005-05-12 2012-05-30 清华大学 核仁素辅助的癌症诊断与治疗方法
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
WO2011123945A1 (en) * 2010-04-06 2011-10-13 The University Of British Columbia Compostions, methods and uses for treating respiratory syncytial virus infection
EP2714094B1 (en) 2011-06-02 2016-02-24 The University of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles
US20130023479A1 (en) * 2011-07-22 2013-01-24 Protgen Ltd. Use of nucleolin as a biomarker for lymphangiogenesis in cancer prognosis and therapy
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
WO2017011411A1 (en) * 2015-07-10 2017-01-19 Ohio State Innovation Foundation Methods and compositions relating to anti-nucleolin recombinant immunoagents
CN106405096A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备胃癌诊断试剂和治疗药物中的应用
CN106405084A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备肠癌诊断试剂和治疗药物中的应用
WO2017181049A1 (en) * 2016-04-15 2017-10-19 Charlestonpharma, Llc Anti-nucleolin agents
CN116754768B (zh) * 2023-05-30 2024-03-29 中山大学附属第五医院 Ddx24在维持内皮细胞的核仁稳态中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
JP2000502450A (ja) 1995-12-22 2000-02-29 アボツト・ラボラトリーズ 蛍光偏光免疫アッセイによる診断法
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US6201104B1 (en) 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
CN1266064A (zh) * 1999-03-03 2000-09-13 华西医科大学 血管生成抑制因子—内皮抑素及其制备方法
JP2003180368A (ja) 2001-12-19 2003-07-02 Pharma Design Inc 癌患者に対する放射線治療の有効性の予測方法
US7544767B2 (en) * 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
WO2003087124A2 (en) * 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7078485B2 (en) 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
JP2007525167A (ja) * 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
JP2007503844A (ja) * 2003-05-20 2007-03-01 ファイザー・プロダクツ・インク 血管新生が関与する障害を診断しかつ治療するための方法及び組成物
CN1862258B (zh) 2005-05-12 2012-05-30 清华大学 核仁素辅助的癌症诊断与治疗方法

Also Published As

Publication number Publication date
EP2375251B1 (en) 2015-04-08
HK1162667A1 (en) 2012-09-21
US20230174644A1 (en) 2023-06-08
CN102539734A (zh) 2012-07-04
JP4742142B2 (ja) 2011-08-10
CN1862258B (zh) 2012-05-30
AU2010241351A1 (en) 2010-12-02
CN102539734B (zh) 2016-02-03
EP2375251A1 (en) 2011-10-12
JP2008541066A (ja) 2008-11-20
ES2369383T3 (es) 2011-11-30
ES2538344T3 (es) 2015-06-19
CN1862258A (zh) 2006-11-15
EP1912066A1 (en) 2008-04-16
DK1912066T3 (da) 2011-10-24
ATE516499T1 (de) 2011-07-15
US11434288B2 (en) 2022-09-06
AU2006246197A1 (en) 2006-11-16
US20090191224A1 (en) 2009-07-30
AU2010241351B2 (en) 2013-04-04
EP1912066A4 (en) 2008-10-15
US20060258605A1 (en) 2006-11-16
WO2006119706A1 (fr) 2006-11-16
EP1912066B1 (en) 2011-07-13
CA2607832A1 (en) 2006-11-16
AU2006246197B2 (en) 2010-08-19
JP5502652B2 (ja) 2014-05-28
JP2011013225A (ja) 2011-01-20
JP2014032203A (ja) 2014-02-20
JP5758962B2 (ja) 2015-08-05

Similar Documents

Publication Publication Date Title
HK1114903A1 (en) Auxiliary method for diagnosis and therapy of cancer with nucleolin
WO2007031091A3 (en) Rna antagonist compounds for the modulation of p21 ras expression
EP1961827A3 (en) Epigenetic methods and nucleic acids for the detection of breast cell proliferative disorders
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
PH12012500758A1 (en) STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFa
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
WO2006110599A3 (en) Cacna1e in cancer diagnosis, detection and treatment
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
ATE450547T1 (de) Eml4-alk-fusionsgen
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
SG155931A1 (en) Wnt proteins and detection and treatment of cancer
EP3070097A3 (en) Citrullinated peptides for diagnosing and prognosing rheumatoid arthritis
WO2007103558A3 (en) Hybrid energy transfer for nucleic acid detection
WO2002086448A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2005001092A3 (en) Compositions and methods for diagnosing and treating cancers
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
WO2009015294A8 (en) Biomarkers for human papillomavirus-associated cancers
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
WO2005085861A3 (en) Nucleic acids and encoded polypeptides for use in liver disorders and epithelial cancer
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
WO2010045495A3 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
WO2006110587A3 (en) Ddr2 in cancer diagnosis, detection and treatment
HK1126278A1 (en) Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha pdgfr(nsclc)
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190511